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Nowadays, treatment of food allergy only considered the avoidance of the specific food. However, the possibility of cross-reactivity
makes this practice not very effective. Immunotherapy may exhibit as a good alternative to food allergy treatment. The use of
hypoallergenic molecules with reduced IgE binding capacity but with ability to stimulate the immune system is a promising tool
which could be developed for immunotherapy. In this study, threemutants of Pru p 3, the principal allergen of peach, were produced
based on the described mimotope and T cell epitopes, by changing the specific residues to alanine, named as Pru p 3.01, Pru p 3.02,
and Pru p 3.03. Pru p 3.01 showed very similar allergenic activity as the wild type by in vitro assays. However, Pru p 3.02 and Pru p
3.03 presented reduced IgE binding with respect to the native form, by in vitro, ex vivo, and in vivo assays. In addition, Pru p 3.03
had affected the IgG4 binding capacity and presented a random circular dichroism, which was reflected in the nonrecognition by
specific antibodies anti-Pru p 3. Nevertheless, both Pru p 3.02 and Pru p 3.03 maintained the binding to IgG1 and their ability to
activate T lymphocytes. Thus, Pru p 3.02 and Pru p 3.03 could be good candidates for potential immunotherapy in peach-allergic
patients.
1. Introduction
IgE-mediated allergy is a hypersensitivity disease suffering
from more than 25% of the population in industrialized
countries. Currently, specific immunotherapy is the only
allergen-specific approach for its treatment and for pre-
venting its progression to severe manifestations [1, 2]. The
administration of increasing doses of allergen extracts to
patients is the method most commonly applied. However,
the use of crude extracts has several disadvantages. It could
induce severe anaphylactic side reactions [3] or lead to
sensitization towards new allergens present in themixture [4,
5]. Different strategies have been designed to try to overcome
these negative effects [6], as the use of allergen-derived B
cell peptides [7, 8], allergen-derived T cell epitope containing
peptides [9, 10] or vaccination with allergen-encoding DNA
[11, 12]. In food allergy, immunotherapy is not commonly
used due to the negative side effects, although several studies
have been performed [13, 14].
The use of hypoallergenic mutants would be a good
strategy to avoid the nondesired side effects of immunother-
apy. Hypoallergenic mutants have been developed for several
pollens and foods allergens [15–18], and their utility for
immunotherapy has been studied [19, 20]. These mutants
have altered their capacity to bind IgE, but they still preserve
the capacity to stimulate the immune system, inducing the
proliferation of T lymphocytes and the production of specific
blocking IgG antibodies which compete with IgE. Different
strategies have been designed to develop these mutants
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[21–23], such as destruction of conformation, site-directed
mutagenesis, or oligomerization.
Peach allergy is the most prevalent plant food allergy in
the Mediterranean area, and its major allergen, the LTP, Pru
p 3, is the main plant food allergen in this region [24, 25].The
current management of peach allergy is to avoid its ingestion,
both fresh and processed forms, due to the fact that it could
induce potentially severe reactions [26, 27]. B and T cell
epitopes have been characterized in Pru p 3 [28–30], being
conserved in other LTPs [31].
In the case of the LTPs, some hypoallergenic forms have
been developed by altering the structure of the protein, such
as in Par j 1, pellitory pollen LTP, and Pru p 3 [16, 17]. The
hypoallergenic Par j 1 was developed with the T cell epitope
and IgG responses not affected [16]. However, the Pru p
3 mutant lost the capacity to bind specific IgG antibodies
in mice, which could be a problem in the process of a
successful immunotherapy [17, 32, 33]. Recently, a hybrid
molecule has been characterized as hypoallergenic mutant,
and its application in immunotherapy is possible [34]. The
two allergenic LTPs from pellitory pollen, Par j 1 and Par j
2, were merged and produced as recombinant proteins. The
hybrid showed a decrease in its allergenic capacity [34].
Based on these studies and the characterized Pru p 3
epitopes, we produced three mutant forms of Pru p 3, Pru
p 3.01, Pru p 3.02, and Pru p 3.03, as recombinant proteins,
using site-directed mutagenesis of residues included in its
recently identified epitope [29, 31]. The new LTP forms Pru
p 3.02 and Pru p 3.03 showed a decrease in their IgE binding
capacity with respect to the wild type, with in vitro, ex vivo
and in vivo evidence. However, they conserved their IgG
epitopes and retained their capacity to stimulate T cells,
inducing similar cytokine profiles to the wild type allergen.
2. Methods
2.1. Patients and Sera. Sera from 10 patients with allergy
to peach selected at the Allergy Service of the Fundacio´n
Jime´nez Dı´az (Madrid), Hospital de Basurto (Bilbao), and
Hospital Infanta Leonor (Madrid) were used (age: 16–46;
sex: 55% female, 45% male). All patients had a convincing
clinical history of immediate allergic reactions after peach
ingestion (urticaria/angioedema or anaphylactic symptoms);
a positive response in the skin prick test (SPT) using a
commercial peach peel extract (ALK-Abello, Madrid, Spain);
and a positive response to peach by open oral challenge,
except patients that had suffered from anaphylaxis [35, 36].
Written informed consent was obtained from all patients
and the study was approved by the ethics committees of the
corresponding hospitals (Fundacio´n Jime´nez Dı´az, Madrid,
spain; Hospital de Basurto, Bilbao, Spain; Hospital Infanta
Leonor, Madrid, Spain).
2.2. Production of Wild Type and Mutant Forms of Pru p 3.
Site-directed mutagenesis to generate Pru p 3 mutants was
performed with appropriate PCR amplification primers and,
as a template, the previously obtained cDNA encoding Pru p
3 [37]. All substitutionsweremade to alanine.The production
of recombinant proteins was performed in Pichia pastoris
yeast following the manufacturer’s recommendations (Invit-
rogen Corporation, De Schelp,TheNetherlands).The recom-
binant proteins were purified from induced supernatants by
two chromatographic steps: gel filtration on a Superdex HR
75 16/26 column (Pharmacia Biotech, Piscataway, NJ, USA)
followed by RP-HPLC on a Nucleosil 300-C4 column (7 ×
250mm; particle size 5 𝜇g; Tecknokroma, Barcelona, Spain).
Purified proteins were quantified by means of the com-
mercial bicinchoninic acid test (Pierce, Cheshire, UK), and
purity was measured by SDS-PAGE, N-terminal amino acid
sequencing with an Applied Biosystems 477A gas-phase
sequencer (Applied Biosystems, Foster City, CA, USA), mass
spectrophotometric analysis with a Biflex III Spectrometer
(Bruker-Franzen Analytik, Bremen, Germany), and finger-
printing after tryptic digestion, using standard methods.
Circular dichroism (CD) measurements were performed
on a Jasco Model J-720 spectropolarimeter (Japan Spectro-
scopic Co., Tokyo, Japan), using a quartz cell with a 1mm light
path length, thermostatically controlled with a Jasco Model
423S Peltier-type temperature controller, and a thermostated
cell holder, interfaced with a thermostatic bath. The far-UV
spectra were recorded at 20∘C from 190 to 260 nm, as an
average of five scans, after being corrected by sustration of a
buffer blank.The protein concentration was in the range 0.2–
0.25mg/mL. Mean residue mass ellipticities were expressed
in terms of (−) (degree cm2 dmol−1).
To compare the activity of wild type with the mutant
forms, the concentration of the proteins was calibrated by
amino acid analysis following the standard ion-exchange
chromatographic method in a Pharmacia Biochrom 20 ana-
lyzer.
For cell culture, the absence of LPS in the sample was
checked by anti-LPS antibodies (rabbit anti-Escherichia coli
LPS; AbD Serotec, Kidlington, UK) and using THP1-XBlue
cells (Invivogen, Toulouse, France).
2.3. Specific IgE and IgGs ELISA Assays. Specific IgE, IgG1,
and IgG4 were determined by direct ELISA assay as previ-
ously reported [38, 39], using sera from patients, goat anti-
human IgE peroxidase (Biosource, Camarillo, CA, USA),
and mouse anti-human-IgG1 or -IgG4 antibodies (Invitro-
gen) with the corresponding secondary antibodies. Blocking
solution (Sigma, St. Louis, MO, USA) without solid phase
was used as negative control, and O.D. values greater than
mean [OD] + 3x SD to the negative control were considered
positive.The sera dilutionwas determined by titration curves.
ELISA-inhibition assays were carried out incubating
single sera or pool (3 h at 25∘C) with the corresponding
inhibitor before adding the solution to the solid phase. The
appropriate concentration of the inhibitor was selected by
titration curves.
2.4. Basophil Activation Test (BAT). Wild type Pru p 3 and
the mutant forms, Pru p 3.01, Pru p 3.02, and Pru p 3.03, were
tested by performing the BATwithwhole blood samples from
4 peach-allergic donors (Table 1), as previously described
[40, 41]. Blood samples were obtained from 4 patients at
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Table 1: Demographic data and basophil activation to the native and mutant forms of Pru p 3 in patients with peach allergy.
Patient Age (years) Sex
% activated basophils (SI)∗
1 𝜇g/mL
Pru p 3 Pru p 3.01 Pru p 3.02 Pru p 3.03
1 40 F 18 (2.5) — — —
2 38 F 24.3 (7.36) — — —
3 55 M 20 (6.66) 21.8 (7.26) 20 (6.66) 22 (7.33)
4 39 M 24 (2.67) 23 (2.55) — —
F: female; M: male; —: negative response.
∗% activated basophils ≥ 15% and SI ≥ 2 were considered positive response.
the Servicio de Alergia, Fundacio´n Jime´nez Dı´az (Madrid)
and Hospital Infanta Leonor (Madrid). The criteria for the
selection were the same as described above.
Following separation of blood cells, 50𝜇L of the patient’s
cell suspension was incubated with 50𝜇L of two final con-
centrations of the tested samples: 10 and 1 𝜇g/mL for Pru p 3,
Pru p 3.01, Pru p 3.02, and Pru p 3.03. As a positive control, a
monoclonal anti-IgE receptor antibody (Bethyl Laboratories,
Montgomery, TX, USA) was used at a final concentration
of 1 𝜇g/mL. The test was considered positive when the %
of positive response was >15% and the stimulation index
(SI, calculated as the percentage of activated basophils with
allergen to the percentage of activated basophils at baseline
conditions) was ≥2. The dilution corresponding to 1𝜇g/mL
was selected as the most appropriate for these samples.
2.5. Proliferation Assays with T Cell Lines from Peach-Allergic
Patients. PBMCs were freshly isolated from whole blood
subjected to density gradient centrifugation on Lymphoprep
(Axis-Shield, Oslo, Norway), as previously described [30].
Cultures were established in 24-well plates (Costar, NY,
USA) at 2 × 106 cells per well and treated with Pru p 3
(10 𝜇g/mL) in RPMI media (Invitrogen), supplemented
with 10% (v/v) of fetal calf serum (Invitrogen), 0.02mM
mercaptoethanol, 2mM glutamine, and 10mM HEPES at
37∘C, in a 5% CO
2
humidified atmosphere. After 5 days, a
half-volume medium was removed and suboptimal doses
of rIL2 (10 ng/mL; Invitrogen) were added. Cultures were
continued for an additional 7 days. On the 12th day, fresh
media supplemented with rIL2 was added in the presence of
105 autologous-mitomycin-treated PBMCs. Finally (on the
19th day of culture), specific TCLs (5 × 104 cells per well)
and their mitomycin-treated PBMCs (105 cells per well) were
seeded in 96 wells. The allergens, peptides, or mutants were
added to the TCL culture in triplicate wells for 48 h. Within
the last 16 h, [3H]-thymidine (0.5 𝜇Ci/well) was added, and
the incorporated radioactivity was measured by scintillation
counting. Phytohemagglutinin-L from Phaseolus vulgaris
(PHA, 1 𝜇g/mL; Roche, Mannheim, Germany) was used as
a positive control. The stimulation index (SI) was calculated
as the ratio between counts of antigen-stimulated cultures
and counts without any activator. A SI ≥ 2 was considered a
positive value.
2.6. HLA Class II Blocking Assays. To demonstrate the
specificity of the proliferation in TCLs experiments, human
leukocyte antigen (HLA) class II inhibition assays were
performed using specific antibodies, as previously described
[42]. Specific TCLs (5 × 104 cells per well) and their
mitomycin-treated PBMCs (105 cells per well) were seeded
in 96 wells (see above). They were incubated with 0.5 and
5 𝜇g/mL of anti-HLA-DP/DQ/DR (AbSerotec, Dusseldorf,
Germany) or isotype control antibodies (Alpha Diagnostic
International Inc., San Antonio, TX, USA) for 2 h at 37∘C
before addition of the corresponding allergen or its mutants
and testing of the proliferative response.
2.7. Determination of IL4, IFN𝛾, and IL10 Levels in TCL
Cultures. Cytokine levels were quantified using 50 𝜇L of
TCL supernatants, by means of matched antibody pairs
according to themanufacturer’s instructions (sensitive limits:
IL4, 0.6 pg/mL; IFN𝛾, 2 pg/mL; IL10, 1.2 pg/mL; Immuno-
Tools, Friesoythe, Germany). Cultures containing TCLs with
mitomycin-treated PBMCs alone served as negative con-
trols. IFN𝛾/IL4 ratios over 10, between 2 and 10, and less
than 2 were, respectively, considered as Th1, Th0, and Th2-
responses.
2.8. Phenotype Analysis of TCLs Using Real-Time PCR.
mRNA from the TCLswas isolated according to theQuiagen-
RNeasy protocol (Quiagen, Valencia, CA, USA) and stored at
−80∘C. RT-PCR was performed as previously described [37,
43]. cDNA was amplified using the Power SYBR Green PCR
Master Mix (Applied Biosystems) according to the manufac-
turer’s recommendations and run on aa Applied Biosystems
7300 real-time detection system (Applied Biosystem), using
previously described primers (GATA-3, F: 5󸀠-GCGGGC-
TCTATCACAAAATGA-3󸀠, R: 5󸀠-GCTCTCCTGGCTGCA-
GACAGC-3󸀠; Fox p 3, F: 5󸀠-GAAACAGCACATTCCCAG-
AGTTC-3󸀠, R: 5󸀠-ATGGCCCAGCGGATGAG-3󸀠; T-bet, F:
5󸀠-GATGCGCCAGGAAGTTTCAT-3󸀠, R: 5󸀠-GCACAA-
TCATCTGGGTCACATT-3󸀠; ROR𝛾, F: 5󸀠-AAATCTGTG-
GGGACAAGTCG-3󸀠, R: 5󸀠-TGAGGGTATCTGCTCCTT-
GG-3󸀠; EF-1, F: 5󸀠-CTGAACCATCCAGGCCAAAT-3󸀠, R:
5󸀠-GCCGTGTGGCAATCCAAT-3󸀠; [44, 45]. Real-time PCR
conditions were as follows: 10min at 95∘C, 15 s at 95∘C, and
60 s at 60∘C (40 cycles). The amount of GATA-3, Fox p 3,
T-bet, and ROR𝛾𝜏 mRNA expression was normalized with
endogenous control EF-1, and the relative quantification was
performed using the comparative threshold cycle method
(2−ΔΔCt), as described by Livak and Schmittgen [46]. The
changes in gene expression were calculated with respect to
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Figure 1: (a) Alignment of amino acid sequences of the wild type (Pru p 3) and mutant forms (Pru p 3.01, Pru p 3.02,and Pru p 3.03). The
residues shaded in black correspond to the IgE epitope in Pru p 3 or the modified residues in Pru p 3.01, Pru p 3.02, and Pru p 3.03. The
molecular weight (MW) obtained by mass spectrometry is indicated. (b) The recombinant proteins (3𝜇g) were separated by SDS-PAGE and
stainedwith Coomassie Blue (Coomassie) or immunodetected with anti-Pru p 3 antibody (anti-LTP). (c) Far-UV (190–260 nm)CD spectrum
of purified proteins.
the untreated cells. All amplifications were carried out in
duplicate.
2.9. Statistical Analysis. Statistical analysis was performed
using SPSS 17.0 and Statgraphics Centurion XVI. Wild type
and mutants were compared using the Wilcoxon paired
samples test, in the Ig binding ELISA assays, proliferative
responses of T cell lines, cytokine levels, and gene expression.
Values of 𝑃 < 0.05 were considered to be significant.
3. Results
3.1. The Mutant Forms Showed a Reduced IgE Binding
Capacity. Pru p 3 residues involved in B epitopes [29, 31]
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Figure 2: Continued.
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Figure 2: (a) Specific IgE to Pru p 3 forms (wild type, Pru p 3.01, Pru p 3.02, and Pru p 3.03), using sera from peach-allergic patients (single
or pool; 1 : 2 dilution). Blocking solution without solid phase was used as a negative control, and optical density (OD) values > 0.189 units
(𝑛 = 30; mean + 3x SD = 0.108 + 3 × 0.026OD units) were considered positive. All tests were performed in triplicate. (b) Reduction of IgE
binding capacity (%) of the mutants in comparison with wild type was calculated, taking as 100% the value obtained for Pru p 3 (5𝜇g/mL).
∗The number of the patients corresponds to that in Table 1. (c) The inhibition percentage of the IgE binding capacity of wild type form is
represented. Plates were covered with Pru p 3 (3𝜇g/mL), and Pru p 3.01, Pru p 3.0, and Pru p 3.03 were used as inhibitors. All tests were
performed in triplicate.
were modified by site-directed mutagenesis, producing three
mutants as recombinant proteins (Figure 1(a)). The three
mutated forms corresponded to a single peak by both HPLC
and mass spectrometry and yielded a unique amino terminal
sequence. Similarly, Pru p 3.01 and Pru p 3.02 could be
detected as a single band by both Coomassie staining and
polyclonal antibodies to the wild type protein (Figure 1(b)).
However, Pru p 3.03 was observed as multiple bands staining
with Coomassie, and it was slightly detected by Pru p 3-
specific antibody. Evidence for the folding of the mutants was
obtained by CD analysis in the far-UV range (Figure 1(c)).
Application of the convex-constraint analysis method to the
spectrum resulted in a great increase of the random coil in
the Pru p 3.03 form comparing to the wild type. By contrast,
the Pru p 3.01 and Pru 3.02 forms showed an overlapped
spectrum with the native form.
Referring to allergenic activity, Pru p 3.03 showed a
significant reduction in the IgE binding capacity, compared to
the wild type. The recognition of this mutant form by peach-
allergic patients was low, ranging from 32 to 93% of reduction
in IgE binding capacity compared to the wild type (Figures
2(a) and 2(b)), this reduction being statistically significative
(𝑃 = 0.0001). These data suggested that B epitopes in Pru
p 3.03 were altered. The decrease of Pru p 3.03-IgE binding
capacity was confirmed by inhibition ELISA, using a serum
pool from peach-allergic patients, and Pru p 3 wild type as
solid phase (Figure 2(c)). Pru p 3.03 rendered low inhibition
values of the IgE binding of the form, reaching only 60% of
inhibition.
In the case of the other two mutants, Pru p 3.01 and Pru
p 3.02, the reduction in the IgE binding was not as dramatic
as in the case of Pru p 3.03, with only a 12-13% of reduction
for the serum pool (Figures 2(a) and 2(b)). By contrast, the
reduction values of single sera ranged from 1 to 59% for Pru
p 3.01 and from 0 to 46% for Pru p 3.02, being statistically
significative in the case of the latter (𝑃 = 0.0023). Both
forms, Pru p 3.01 and Pru p 3.02, almost completely inhibited
the IgE binding, being a little lower in the case of Pru p 3.02
(Figure 2(c)).
3.2. The Three Pru p 3 Mutants Retained Their Ability to Bind
IgG Blocking Antibodies. To test the capacity to bind IgG
blocking antibodies, direct ELISA assays were also performed
against IgG1 and IgG4 (Figure 3). The three mutant forms
could bind IgG1, without being statistically significant in the
case of Pru p 3.01 and Pru p 3.03 (𝑃 = 0.381 and 0.413,
resp.; Figure 3), indicating that the IgG1 epitopes were mostly
conserved. Curiously, Pru p 3.02 rendered differences with
respect to the wild type (𝑃 = 0.0083) because higher values
were obtained with the mutant (Figure 3).
On the other hand, several patients showed low levels of
specific IgG4 against the native form of Pru p 3 (Figure 3). In
the case of patients with positive response, the IgG4 binding
was similar in Pru p 3.01 and Pru p 3.02 (𝑃 = 0.889 and
0.129, resp.), indicating that these mutants have not affected
these epitopes (Figure 3). Nonetheless, the binding of Pru p
3.03 was decreased (𝑃 = 0.0001), with values ranging from 0
to 97% of reduction, indicating that the IgG4 epitopes were
affected, at least in part.
3.3. Reduced Ex Vivo Allergic Response Induced by the
Mutants. The reduction in the IgE binding observed in vitro
was confirmed by ex vivo assays, because most patients did
not recognize the Pru p 3mutant forms (Table 1).Themutants
did not activate basophils from patients with peach allergy in
most cases (Table 1: 2/4 positive cases Pru p 3.01; 1/4 positive
cases in the case of Pru p 3.02 and Pru p 3.03).
3.4. The T Cell Activation Capacity Was Maintained by
the Pru p 3 Mutants. The proliferative response of Pru p 3
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Figure 3: (a) Specific IgG1 and IgG4 to Pru p 3 forms (wild type, Pru p 3.01, Pru p 3.02, and Pru p 3.03), using serum pool from peach-allergic
patients (1 : 10 dilution). Blocking solution without solid phase was used as a negative control, and optical density (OD) values > 0.086 units
(𝑛 = 20; mean + 3x SD = 0.05 + 3 × 0.012 OD units) were considered positive. All tests were performed in triplicate. (b) Reduction of IgG1
and IgG4 binding capacity (%) of the mutants in comparison with Pru p 3 was calculated by taking the value of Pru p 3 (5𝜇g/mL) to represent
100% in each serum sample. ∗The number of the patients corresponds to that in Table 1. −, negative value, represents those patients with
negative IgG4 for Pru p 3.
specific T-cell lines was measured after culture in presence of
thewild type andmutant forms (Figure 4(a)).The stimulation
index for the positive control (PHA) ranged from 2.6 to 59.8
(data not shown). The mutant forms induced a slightly lower
response compared to the wild type, although no statistical
differences were observed (𝑃 = 0.363, 𝑃 = 0.958, and
𝑃 = 0.494, for Pru p 3.01, Pru p 3.02, and Pru p 3.03,
resp.). So, these results suggest that the mutations did not
affect the T cell epitopes. This proliferation was prevented
by incubation with anti-HLA antibody in a dose-dependent
manner (Figure 4(b)). Isotype control antibody had no effect
(data not shown).
The T cell proliferation in presence of native and mutant
forms produced a Th2 environment and the same T cell
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Figure 4: (a) Proliferative response of Pru p 3 T cell lines from
peach-allergic patients to wild type, mutants (Pru p 3.01, Pru p 3.02,
and Pru p 3.03), LPS, and negative control (PBS), as a measure
of incorporated radioactivity. Medians (—) and range (bars) were
calculated from 𝑛 = 24 values for each protein. Significant
differences between the antigens and untreated culture (PBS) are
indicated. (b) HLA-II restriction specificity of T cell recognition of
wild type and the mutant forms. The inhibition percentage of the
proliferation of specific TCLs to each protein in the presence of anti-
HLA antibodies is represented for patient 2, as an example.
phenotype. In response to the four proteins, IL4, IFN𝛾, and
IL10 were produced in the same way (𝑃 = 0.605, 𝑃 = 0.362,
and 𝑃 = 0.107, for Pru p 3.01, Pru p 3.02, and Pru p 3.03,
resp.) with more production of IL4 than IFN𝛾 (Figure 5(a)).
In this regard, the expression of the transcription factors for
Th1,Th2, Treg andTh17, T-bet, GATA-3, Fox p 3, and ROR𝛾t,
respectively, wasmeasured byRT-qPCR (Figure 5(b)), and no
significant differences were observed.
4. Discussion
Allergen-specific immunotherapy (SIT) represents the most
effective treatment available toward allergies. However, in
food allergy, SIT has not been practiced, mainly for the high
risk to develop anaphylactic side effects for patients [13].
A few years ago, a pioneering study based on sublingual
immunotherapy (SLIT) was performed in peach-allergic
patients, using extracts with quantified amounts of Pru p
3 [14]. The obtained results were limited, probably because
higher amount of allergens and a longer treatment would be
required formore effective immunotherapy.However, the use
of high doses of wild type allergens could present a serious
risk for sensitized patients. This fact and the expensive cost
of this type of treatment do not make their application in
immunotherapy a very popular practice among clinicians.
By contrast, the use of hypoallergenic molecules may
prevent these side effects and reduce cost, allowing us the
use of higher doses of proteins and longer treatments. These
features reveal them as a promising strategy to develop [6, 32].
Hypoallergenic forms could be obtained by differentmethods
such as the search of native isoforms or molecular design
modifying the wild type allergen [47, 48].
The LTPs syndrome is an allergy mediated by members
of this family present in a wide range of plant foods and
some pollen [25]. This means that people sensitized to
LTPs should remove essential foods from their diet to avoid
adverse reactions. However, the avoidance, sometimes, does
not ensure unwanted contacts due to allergen traces in some
processed foods. Nowadays, there are no effective treatments
that improve the quality of life for these patients.
In this work, three Pru p 3 mutant forms have been pro-
duced by site-directed mutagenesis of the essential residues
for IgE binding activity [29, 31]: Pru p 3.01, with four changes
in the central region; Pru p 3.02, with four mutated residues
in the C-terminal coil; and Pru p 3.03, including all modified
residues of the other two. The three mutants retained their
ability to bind blocking antibodies and to stimulate T cell
proliferation. One of the mutants, Pru p 3.01, had a similar
behaviour as the wild type, meaning that the four modified
residues were not enough to abolish the allergenic capacity of
the wild type form in a significant way. The other two, Pru p
3.02 and Pru p 3.03, showed a significant reduction in their
allergenicity capacity, since they had less ability to bind IgE
and less recognition by patients with peach allergy, compared
to the wild type protein.The reduction in cellular response by
basophil activation test in these mutants suggested that their
modifications were affecting the cross-linking on the surface
of the effector cells.
In immunotherapy, several studies have indicated the
importance tomaintain the binding to IgG blocking antibod-
ies. Those antagonize the recognition of wild type allergens
by IgE antibodies captured on the surfaces of mast cells and
basophils, which triggers the allergic reaction [33].
In the case of the mutants produced in this study, Pru p
3.01, Pru p 3.02, and Pru p 3.03, their ability to bind IgG1 was
retained. In fact, some patients showed higher IgG1 binding
to Pru p 3.02 and Pru p 3.03 than to wild type, probably
due to the fact that some modified residues produced better
recognition to IgG1.
In the case of IgG4, while Pru p 3.01 and Pru p 3.02
rendered no differences comparing to the wild type, Pru
p 3.03 showed a reduced ability to bind it. This behaviour
may be explained in terms of overlapping between IgE and
IgG4 epitopes, or because the loss of folding observed in
this form could alter the binding to IgE and IgG4 but not
to IgG1. In a recent paper [17], a reduced form of Pru p
3 was developed as a recombinant protein by modification
of its six cysteines present in the primary structure. This
unfolded mutant exhibited the ability to bind specific IgGs
from sensitized mice (IgG1 and IgG2) completely abolished.
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Figure 5: (a)The ratio between IFN𝛾 and IL4 for T cell line supernatants stimulated with Pru p 3 and its mutant forms is represented (𝑛 = 6).
Statistical analysis was performed by a paired-samples Wilcoxon test (𝑃 < 0.05). Medians (—) and ranges (bars) are shown. (b) GATA-3, Fox
p 3, T-bet, and ROR𝛾𝜏 relative gene expression levels for T cell lines from peach-allergic patients (𝑛 = 6). The results are expressed in fold
change comparing nonstimulated with stimulated conditions, and statistical significance is indicated (𝑃 < 0.05) after performing aWilcoxon
test for paired samples. Medians (—) and ranges (bars) are represented.
Thus, the loss of 3D structure may imply the loss of some
conformational epitopes, especially affecting IgE and IgG4
epitopes, in our Pru p 3.03mutant.
Besides the loss of IgE binding and the maintaining
of blocking IgG recognition, it is essential for a successful
immunotherapy that the hypoallergenic mutants also retain
their capacity to stimulate the immune system [49], preserv-
ing their T cell epitopes. In our case, it was critical because one
of the main T cell epitopes described in Pru p 3, Pru p 3
65–80
[30, 50], was located in the same region as the C-terminal
epitope. In the case of Pru p 3.01, the mutations did not affect
T epitopes, and the T cell proliferation was not affected, as
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predictable. By contrast, the modifications in Pru p 3.02 and
Pru p 3.03 could have interfered.However, both retained their
ability to stimulate the proliferation of specific T cell lines,
suggesting that their modified residues did not affect T cell
epitopes.
Summarizing, in this work we have generated two hypoal
lergenic forms, Pru p 3.02 and Pru p 3.03, which could be
promising tools to be used in immunotherapy for peach-
allergic patients.
Pru p 3.03 had the highest hypoallergenic capacity of the
three mutants. However, this mutant showed a loss of its
three-dimensional structure, which made it more unstable
in solution. This could hinder future applications. But also,
this loss can be the cause of the drop in its IgE and IgG4
binding capacity, though preserving the IgG1 epitopes. By
contrast, Pru p 3.02 retained its ability to bind IgG antibodies,
both IgG1 and IgG4, but exhibiting a considerable reduction
of its allergenic activity, in both IgE binding capacity and
patients’ recognition. These characteristics make it highly
recommendable for use in immunotherapy.
Although, for both Pru p 3.02 and Pru p 3.03, more
detailed studies such as their use in animal models are
necessary to test their effectiveness, the approach presented
in this work may be a first step towards the implementation
of a new strategy for immunotherapy.
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